ESICM News

HOT TOPICS SESSION...

HOT TOPICS SESSION...

HOTTER THAN EVER! 

Don't miss the most highly-anticipated session of the congress. Results from six long-awaited scientific trials will be presented publicly for the first time and some of the corresponding papers will be simultaneously published in a major medical journal. Data that has been embargoed until today will be revealed... Take advantage of this rare chance and ensure YOU are among the first of your colleagues to hear the results, pose questions directly to the speakers and discuss the clinical implications of their findings!

Chairs ESICM President Daniel De Backer and JAMA Editor-In-Chief Howard Bauchner lead this  always hotly anticipated session that begins by recognising the best in future studies, with presentation of ESICM & Industry Awards and then features presentations releasing the newest data from the most exciting clinical trials in ICM.

Here is what is featured at HOT TOPICS @ LIVES 2014:

The effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs Evelien Oostdijk (Utrecht, Netherlands)

The VITdAL@ICU trial: Correction of vitamin D deficiency in critically ill patients Karin Amrein (Graz, Austria)

Early high-dose erythropoietin therapy after out-of-hospital cardiac arrest: A multicentre, randomised controlled trial (EPO-ACR 02) Alain Cariou (Paris, France)

Early goal directed therapy in sepsis: The ARISE trial Sandra Peake (Adelaide, Australia)

Transfusion threshold in septic shock: The TRISS trial Lars Holst (Copenhagen, Denmark)

Calories: A phase III multicentre RCT comparing early nutritional support with parenteral versus enteral routes Kathy Rowan (London, United Kingdom)

Don't miss this amazing session... 

Can't wait? Check out our icTV interviews with several of these presenters! Find out more about our 2014 ESICM & Industry Award Winners here.

HOT TOPICS SESSION

01.10.2014, 14:10 – 16:30 - room Barcelona

OR 

You can WATCH ONLINE HERE

<Back to the news list
Comment on this news Comment on this news
To respond to this article, thank you for identifying
ReactionsReactions (0)